I am a DPhil student in Prof John Frater’s group and I am interested in exploring HIV-host interaction and how this might affect the host response in novel therapeutic strategies for HIV cure. Specifically, I investigate broadly neutralising antibody resistance in people who live with HIV and gene signatures that predict time response to treatment.
I completed my BSc in Biomedical Informatics and MSc in Cancer Pathology in Greece before I came to Oxford, where I have spent a few years as a Research Assistant, working first with rare cancers and then with HIV.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Frater J. et al, (2021), Lancet HIV, 8, e474 - e485
Cost-effectiveness of healthcare interventions for rare cancers: Evidence from a systematic literature review and meta-analysis
Rodriguez-Martin AM. et al, (2018), Journal of Cancer Policy, 18, 1 - 10
Inadvertent parathyroidectomy risk factors in 1,373 thyroidectomies-male gender and presence of lymphadenopathy, but not size of gland, independently increase the risk.
Christakis I. et al, (2017), Gland Surg, 6, 666 - 674
Clinicopathological characteristics and BRCA1/2 mutation rate in male breast cancer: a retrospective case series by the Hellenic Society of Medical Oncology
Lypas G. et al, (2016), Annals of Oncology, 27
Experience and Influence from a Psycho-oncology Seminar Organized by Hellenic Group of Young Oncologists
Nikolaou M. et al, (2015), PSYCHO-ONCOLOGY, 24, 304 - 305